B-type natriuretic peptide is an important prognostic marker in heart failure. However, there are limited data for its value in non-cardiac intensive care unit patients, namely regarding long-term prognosis. We investigated the long-term prognostic value of BNP in a cohort of critically ill patients. This was a prospective and observational study, conducted in a tertiary university hospital 20-bed intensive care unit. We included 103 mechanically- ventilated patients admitted for a noncardiac primary diagnosis; B-type natriuretic peptide samples were obtained on admission. A mean 14 (3-30) month follow up was available in 96.1% of patients who were discharged from hospital. Mean age was 60.7±19.0 years and mean APACHE II score was 16.2±7.2. APACHE II score and renal dysfunction increased with rising B-type natriuretic peptide, with more than 60% of patients having Btype natriuretic peptide levels of 100 pg/mL or over; echocardiography-derived left ventricular ejection fraction was lower in patients with higher B-type natriuretic peptide (P < 0.001). Long-term survivors had lower median B-type natriuretic peptide values (117.5[2-1668] pg/mL) compared with intensive care unit non-survivors (191.0[5-4945] pg/mL), P<0.001. After adjustment to APACHE II score, B-type natriuretic peptide levels of 300 pg/mL or over were independently associated with long-term mortality (odds-ratio 4.1 [95% CI 1.45-11.5], P=0.008). We conclude that in an unselected cohort of intensive care unit patients, admission B-type natriuretic peptide is frequently elevated, even without clinically apparent acute heart disease, and is a strong independent predictor of long-term mortality.
BNP, critical illness, prognosis, mortality.
Rui Baptista Cardiology Department, Coimbra University Hospital and Medical School Praceta Mota Pinto, 3000-001 Coimbra, Portugal. Tel: + 351.918523940. E-mail: email@example.com
Share this Article
Related Content In Heart Failure
Explaining Sex Differences in Cardiac Resynchronisation Therapy Outcome
European Journal of Arrhythmia & Electrophysiology. 2020;6(1):17-23 DOI: https://doi.org/10.17925/EJAE.2020.6.1.17
Over the past years, several reports have drawn attention to the need to consider sex-specific differences in cardiac resynchronisation therapy (CRT). Most importantly, there is growing concern on the underrepresentation of women in CRT landmark trials which laid the foundation for present guidelines. Patients with symptomatic heart failure, reduced left ventricular ejection fraction (LVEF) ≤35% […]
Quantification of Seasonal Variation in Daily Physical Activity in Individuals with Heart Failure and Implantable Cardioverter Defibrillator/Cardiac Resynchronisation Therapy Devices
Heart International. 2019;13(2):31–7
In individuals with heart failure (HF) who also have implanted cardioverter defibrillators and/or cardiac resynchronisation therapy (ICD/CRT) devices, low daily physical activity (PA) levels lead to increased risk of mortality, poor aerobic capacity and lower health-related quality of life.1 Improving daily PA in these individuals may, therefore, be an important clinical endpoint; however, designing interventional […]
Normalised Heart Rate Variability After Sacubitril/Valsartan
European Journal of Arrhythmia & Electrophysiology. 2019;5(1):60-1 DOI: https://doi.org/10.17925/EJAE.2019.5.1.60
We report the case of a 44-year-old woman with a history of chronic heart failure with reduced ejection fraction (HFrEF) due to ischemic cardiomyopathy (New York Heart Association [NYHA] class II). In 2010, she had a myocardial infarction with thrombotic occlusion of the left anterior descending coronary artery, alleged in the context of an essential thrombocythaemia. […]
Journal articles and more to your inbox
Get the latest clinical insights from touchCARDIOSign me up!